WUXI BIOLOGICS (CAYMAN) INC revenue breakdown overview

WUXI BIOLOGICS (CAYMAN) INC revenue for the last year amounted to 18.74 B HKD, the most of which — 16.72 B HKD — came from its highest performing source at the moment, Biologics, the year earlier bringing 2.58 B HKD. The greatest contribution to the revenue figure was made by North America — last year it brought WUXI BIOLOGICS (CAYMAN) INC 8.92 B HKD, and the year before that — 9.88 B HKD.